Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study. (2025)

[OBJECTIVE] This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.

[METHODS] In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.

[RESULTS] We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.2 %) experienced relapse (median follow-up: 65 months). The no specific molecular profile (NSMP) subgroup (n = 60) showed longer time to progression than the mismatch repair deficient (MMRd, n = 95; P = 0.047) and p53-abnormal